Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,268 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
RALB GTPase: a critical regulator of DR5 expression and TRAIL sensitivity in KRAS mutant colorectal cancer.
Khawaja H, Campbell A, Roberts JZ, Javadi A, O'Reilly P, McArt D, Allen WL, Majkut J, Rehm M, Bardelli A, Di Nicolantonio F, Scott CJ, Kennedy R, Vitale N, Harrison T, Sansom OJ, Longley DB, Evergren E, Van Schaeybroeck S. Khawaja H, et al. Among authors: harrison t. Cell Death Dis. 2020 Oct 29;11(10):930. doi: 10.1038/s41419-020-03131-3. Cell Death Dis. 2020. PMID: 33122623 Free PMC article.
FLIP: A Targetable Mediator of Resistance to Radiation in Non-Small Cell Lung Cancer.
McLaughlin KA, Nemeth Z, Bradley CA, Humphreys L, Stasik I, Fenning C, Majkut J, Higgins C, Crawford N, Holohan C, Johnston PG, Harrison T, Hanna GG, Butterworth KT, Prise KM, Longley DB. McLaughlin KA, et al. Among authors: harrison t. Mol Cancer Ther. 2016 Oct;15(10):2432-2441. doi: 10.1158/1535-7163.MCT-16-0211. Epub 2016 Jul 29. Mol Cancer Ther. 2016. PMID: 27474150
Development of a potent and selective cell penetrant Legumain inhibitor.
Ness KA, Eddie SL, Higgins CA, Templeman A, D'Costa Z, Gaddale KK, Bouzzaoui S, Jordan L, Janssen D, Harrison T, Burkamp F, Young A, Burden R, Scott CJ, Mullan PB, Williams R. Ness KA, et al. Among authors: harrison t. Bioorg Med Chem Lett. 2015 Dec 1;25(23):5642-5. doi: 10.1016/j.bmcl.2015.10.001. Epub 2015 Oct 9. Bioorg Med Chem Lett. 2015. PMID: 26522952
P3 SAR exploration of biphenyl carbamate based Legumain inhibitors.
Higgins C, Bouazzaoui S, Gaddale K, D'Costa Z, Templeman A, O'Rourke M, Young A, Scott C, Harrison T, Mullan P, Williams R. Higgins C, et al. Among authors: harrison t. Bioorg Med Chem Lett. 2014 Jun 1;24(11):2521-4. doi: 10.1016/j.bmcl.2014.04.002. Epub 2014 Apr 12. Bioorg Med Chem Lett. 2014. PMID: 24775305
Identification and SAR exploration of a novel series of Legumain inhibitors.
Eddie SL, Gregson A, Graham E, Burton S, Harrison T, Burden R, Scott CJ, Mullan PB, Williams R. Eddie SL, et al. Among authors: harrison t. Bioorg Med Chem Lett. 2019 Jun 15;29(12):1546-1548. doi: 10.1016/j.bmcl.2019.03.019. Epub 2019 Mar 29. Bioorg Med Chem Lett. 2019. PMID: 31005445
FKBPL and peptide derivatives: novel biological agents that inhibit angiogenesis by a CD44-dependent mechanism.
Valentine A, O'Rourke M, Yakkundi A, Worthington J, Hookham M, Bicknell R, McCarthy HO, McClelland K, McCallum L, Dyer H, McKeen H, Waugh DJ, Roberts J, McGregor J, Cotton G, James I, Harrison T, Hirst DG, Robson T. Valentine A, et al. Among authors: harrison t. Clin Cancer Res. 2011 Mar 1;17(5):1044-56. doi: 10.1158/1078-0432.CCR-10-2241. Epub 2011 Mar 1. Clin Cancer Res. 2011. PMID: 21364036 Free PMC article.
Identification and Structure-Guided Development of Pyrimidinone Based USP7 Inhibitors.
O'Dowd CR, Helm MD, Rountree JSS, Flasz JT, Arkoudis E, Miel H, Hewitt PR, Jordan L, Barker O, Hughes C, Rozycka E, Cassidy E, McClelland K, Odrzywol E, Page N, Feutren-Burton S, Dvorkin S, Gavory G, Harrison T. O'Dowd CR, et al. Among authors: harrison t. ACS Med Chem Lett. 2018 Feb 21;9(3):238-243. doi: 10.1021/acsmedchemlett.7b00512. eCollection 2018 Mar 8. ACS Med Chem Lett. 2018. PMID: 29541367 Free PMC article.
2,268 results